Scientists discuss and refer to previous scientific publications in their scientific articles. These citations to the scientific literature are an integral part of the scientific process. Some of the hundreds of scientific citations to the published articles of TransBarrier® physicians, are listed below. TransBarrier’s scientific findings have been published in multiple, peer-reviewed medical journals, including BMC Neurology, Clinical Drug Investigation, Clinical Therapeutics, CNS Drugs, Current Alz. Research, Current Medical Research and Opinion, Drug Discovery Today, Expert Review of Neurotherapeutics; and in medical and scientific textbooks, including Mechanisms of Neuroinflammation (InTech, 2017); and New Therapeutics for Traumatic Brain Injury (Academic Press, 2017).
[divider]
Citations to publications of TransBarrier Physicians:
In 2019:
- Clark, I.A. and B. Vissel, Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective – a Commentary. Expert Rev Neurother, 2019. 19(6): p. 535-543. (FREE FULL TEXT)
- M.J., S. Giorgi-Coll, A. Helmy, P.J. Hutchinson, and K.L. Carpenter, Metabolism and inflammation: implications for traumatic brain injury therapeutics. Expert Rev Neurother, 2019. 19(3): p. 227-242.
- Batsaikhan, B., J.Y. Wang, M.T. Scerba, D. Tweedie, N.H. Greig, J.P. Miller, B.J. Hoffer, C.T. Lin, and J.Y. Wang, Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6′-Dithiothalidomide on Traumatic Brain Injury. Int J Mol Sci, 2019. 20(3).
- Wang, D., Tumor Necrosis Factor-Alpha Alters Electrophysiological Properties of Rabbit Hippocampal Neurons. JAD, 2019. 68(3): p. 1257-1271.
-
Herman, F.J., S. Simkovic, and G.M. Pasinetti, Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets .Br J Pharmacol, 2019.
- OTHER 2019 CITATIONS PENDING
In 2018:
- Ekert, J.O., R.L. Gould, G. Reynolds, and R.J. Howard, TNF alpha inhibitors in AD: A systematic review. Int J Geriatr Psychiatry, 2018. 33(5): p. 688-694.
- Tubbs, R.S., A. Demerdash, M. Loukas, J. Cure, R.J. Oskouian, S. Ansari, and A.A. Cohen-Gadol, Intracranial Connections of the Vertebral Venous Plexus: Anatomical Study with Application to Neurosurgical and Endovascular Procedures at the Craniocervical Junction.Oper Neurosurg (Hagerstown), 2018. 14(1): p. 51-57.
- Hasturk, A.E., E.C. Gokce, E.R. Yilmaz, B. Horasanli, O. Evirgen, N. Hayirli, H. Gokturk, I. Erguder, and B. Can, Therapeutic Evaluation of Tumor Necrosis Factor-alpha Antagonist… against Traumatic Brain Injury in Rats: Ultrastructural, Pathological, and Biochemical Analyses.Asian J Neurosurg, 2018. 13(4): p. 1018-1025.
- Wang, W., A.K. Zinsmaier, E. Firestone, R. Lin, T.A. Yatskievych, S. Yang, J. Zhang, and S. Bao, Blocking Tumor Necrosis Factor-Alpha Expression Prevents Blast-Induced Excitatory/Inhibitory Synaptic Imbalance and Parvalbumin-Positive Interneuron Loss in the Hippocampus.J Neurotrauma, 2018. 35(19): p. 2306-2316.
- OTHER 2018 CITATIONS PENDING
In 2017:
- Allison, D.J., A.R. Josse, D.A. Gabriel, P. Klentrou, and D.S. Ditor, Targeting inflammation to influence cognitive function following spinal cord injury: a randomized clinical trial. Spinal Cord, 2017. 55(1): p. 26-32.
- Bagyinszky, E., V.V. Giau, K. Shim, K. Suk, S.S.A. An, and S. Kim, Role of inflammatory molecules in the AD progression and diagnosis. J Neurol Sci, 2017. 376: p. 242-254.
- Barami, K., Letter: Low-Pressure Hydrocephalus in Children: A Case Series and Review of the Literature. Neurosurgery, 2017. 81(5): p. E66.
- Chang, R., J. Knox, J. Chang, A. Derbedrossian, V. Vasilevko, D. Cribbs, R.J. Boado, W.M. Pardridge, and R.K. Sumbria, Blood-Brain Barrier Penetrating Biologic TNF-alpha Inhibitor for AD. Mol Pharm, 2017. 14(7): p. 2340-2349.
- Chang, R., K.L. Yee, and R.K. Sumbria, Tumor necrosis factor alpha Inhibition for AD. J Cent Nerv Syst Dis, 2017. 9: p. 1179573517709278.
- Clark, I.A., An unsound AAN Practice Advisory Expert Rev Neurother, 2017. 17(3): p. 215-217.
- Clark, I.A. and B. Vissel, The meteorology of cytokine storms, and the clinical usefulness of this knowledge. Semin Immunopathol, 2017. 39(5): p. 505-516.
- Dasli, S., M. Topdag, A. Mutlu, A. Kara, and M. Ozturk, Prophylactic … treatment in cisplatin ototoxicity. Eur Arch Otorhinolaryngol, 2017. 274(10): p. 3577-3583.
- Deardorff, W.J. and G.T. Grossberg, Targeting neuroinflammation in AD: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother, 2017. 17(1): p. 17-32.
- Decourt, B., D.K. Lahiri, and M.N. Sabbagh, Targeting Tumor Necrosis Factor Alpha for AD. Curr Alz Res, 2017. 14(4): p. 412-425.
- Donat, C.K., G. Scott, S.M. Gentleman, and M. Sastre, Microglial Activation in Traumatic Brain Injury. Front Aging Neurosci, 2017. 9: p. 208.
- Frega, G., I. Garajova, A. Palloni, M.A. Barbera, M. Trossello Pastore, L. Faccioli, L. Spinardi, S. De Lorenzo, M. Cubelli, M.A. Pantaleo, G. Biasco, and G. Brandi, Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients. Oncology, 2017.
- Hollander, M.C., L.L. Latour, D. Yang, H. Ishii, Z. Xiao, Y. Min, A. Ray-Choudhury, J. Munasinghe, A.S. Merchant, P.C. Lin, J. Hallenbeck, M. Boehm, and L. Yang, Attenuation of Myeloid Specific TGFbeta Signaling Induces Inflammatory Cerebrovascular Disease and Stroke. Circ Res, 2017.
- Leyns, C.E.G. and D.M. Holtzman, Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener, 2017. 12(1): p. 50.
- Li, B., Y. Gao, W. Zhang, and J.R. Xu, Regulation and effects of neurotrophic factors after neural stem cell transplantation in a transgenic mouse model of AD. J Neurosci Res, 2017.
- Menzel, L., L. Kleber, C. Friedrich, R. Hummel, L. Dangel, J. Winter, K. Schmitz, I. Tegeder, and M.K. Schafer, Progranulin protects against exaggerated axonal injury and astrogliosis following traumatic brain injury. Glia, 2017. 65(2): p. 278-292.
- Misiak, B., J.A. Beszlej, K. Kotowicz, M. Szewczuk-Boguslawska, J. Samochowiec, J. Kucharska-Mazur, and D. Frydecka, Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets. Prog Neuropsychopharmacol Biol Psychiatry, 2018. 80(Pt C): p. 177-188.
- Mohlenhoff, B.S., A. O’Donovan, M.W. Weiner, and T.C. Neylan, Dementia Risk in Posttraumatic Stress Disorder: the Relevance of Sleep-Related Abnormalities in Brain Structure, Amyloid, and Inflammation. Curr Psychiatry Rep, 2017. 19(11): p. 89.
- Paouri, E., O. Tzara, G.I. Kartalou, S. Zenelak, and S. Georgopoulos, Peripheral Tumor Necrosis Factor-Alpha (TNF-alpha) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice. J Neurosci, 2017. 37(20): p. 5155-5171.
- Paouri, E., O. Tzara, S. Zenelak, and S. Georgopoulos, Genetic Deletion of Tumor Necrosis Factor-alpha Attenuates Amyloid-beta Production and Decreases Amyloid Plaque Formation and Glial Response in the 5XFAD Model of AD. JAD, 2017. 60(1): p. 165-181.
- Piirainen, S., A. Youssef, C. Song, A.V. Kalueff, G.E. Landreth, T. Malm, and L. Tian, Psychosocial stress on neuroinflammation and cognitive dysfunctions in AD: the emerging role for microglia? Neurosci Biobehav Rev, 2017. 77: p. 148-164.
- Rodriguez-Grande, B., A. Ichkova, S. Lemarchant, and J. Badaut, Early to Long-Term Alterations of CNS Barriers After Traumatic Brain Injury: Considerations for Drug Development. AAPS J, 2017. 19(6): p. 1615-1625.
- Shapira, R., B. Solomon, S. Efrati, D. Frenkel, and U. Ashery, Hyperbaric oxygen therapy ameliorates pathophysiology of 3xTg-AD mouse model by attenuating neuroinflammation. Neurobiol Aging, 2017. 62: p. 105-119.
- Volgyi, K., K. Haden, V. Kis, P. Gulyassy, K. Badics, B.A. Gyorffy, A. Simor, Z. Szabo, T. Janaky, L. Drahos, A. Dobolyi, B. Penke, G. Juhasz, and K.A. Kekesi, Mitochondrial Proteome Changes Correlating with beta-Amyloid Accumulation. Mol Neurobiol, 2017. 54(3): p. 2060-2078.
- Xu, H., Z. Wang, J. Li, H. Wu, Y. Peng, L. Fan, J. Chen, C. Gu, F. Yan, L. Wang, and G. Chen, The Polarization States of Microglia in TBI: A New Paradigm for Pharmacological Intervention. Neural Plast, 2017. 2017: p. 5405104.
- Yang, Y., J. Zhang, Q. Gao, J. Bo, and Z. Ma, … thermal and mechanical hyperalgesia induced by bone cancer. Experimental and Therapeutic Medicine, 2017. 13(5): p. 2565-2569.
In 2014:
*1. Bae WC, Masuda K. Chapter 25: Enhancing Disc Repair by Growth Factors and Other Modalities. In: Shapiro IM, Risbud MV, editors. The Intervertebral Disc. Wien: Springer-Verlag; 2014.
*2. Bastos LF, Coelho MM. Drug repositioning: playing dirty to kill pain. CNS Drugs. 2014;28(1):45-61.
*3. Clark IA, Vissel B. Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflammation. 2014;11(1):51.
*4. Faingold CL. Chapter 7: Network Control Mechanisms: Cellular Inputs, Neuroactive Substances, and Synaptic Changes. In: Faingold CL, Blumenfeld H, editors. Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics: Elsevier; 2014.
*5. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG. Inflammation, defective insulin signaling, and neuronal dysfunction in AD. Alz Dement. 2014;10(1S):S76-S83.
*6. Gisondi P, Sala F, Alessandrini F, Avesani V, Zoccatelli G, Beltramello A, et al. Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology. 2014;228(1):78-85.
*7. Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Venous Drainage of the Spine and Spinal Cord: A Comprehensive Review of its History, Embryology, Anatomy, Physiology, and Pathology. Clinical Anatomy. 2014;epub.
*8. Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W. Insulin resistance, neuroinflammation, and AD. Rev Neurosci. 2014.
*9. Ohtori S, Inoue G, Miyagi M, Takahashi K. Pathomechanisms of discogenic low back pain in humans and animal models. Spine J. 2014.
*10. Sem DS. Repurposing – Finding New Uses for Old (and Patented) Drugs: Bridging the “Valley of Death,” to Translate Academic Research Into New Medicines. Marquette Intellectual Property Law Review. 2014;18(1):139-66.
*11. Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol. 2014.
*12. Starke RM, Raper DM, Ding D, Chalouhi N, Owens GK, Hasan DM, et al. Tumor Necrosis Factor-alpha Modulates Cerebral Aneurysm Formation and Rupture. Transl Stroke Res. 2014;5(2):269-77.
*13. Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, et al. Increased Plasma TACE Activity in Subjects with Mild Cognitive Impairment and Patients with AD. JAD. 2014.
*14. Trager U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, et al. HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain. 2014;137(Pt 3):819-33.
*15. Tronel C, Page G, Bodard S, Chalon S, Antier D. The specific PKR inhibitor C16 prevents apoptosis and IL-1beta production in an acute excitotoxic rat model with a neuroinflammatory component. Neurochem Int. 2014;64:73-83.
*16. Winkelstein BA, Allen KD, Setton LA. Chapter 19: Intervertebral Disc Herniation: Pathophysiology and Emerging Therapies. In: Shapiro IM, Risbud MV, editors. The Intervertebral Disc. Wien, Austria: Springer-Verlag; 2014.
In 2012:
1. Belarbi, K., et al., TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflammation, 2012. 9: p. 23.
2. Bomfim, T.R., et al., An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by AD disease- associated Abeta oligomers. J Clin Invest, 2012. 122(4): p. 1339-53.
3. Butchart, J. and C. Holmes, Systemic and central immunity in AD: therapeutic implications. CNS Neurosci Ther, 2012. 18(1): p. 64-76.
4. Cereda, C., et al., The Role of TNF-alpha in ALS: New Hypostheses for Future Therapeutic Approaches, in Amyotrophic Lateral Sclerosis, M.H. Maurer, Editor. 2012, InTech. p. 413-436.
5. Clark, I., et al., Tumor necrosis factor-induced cerebral insulin resistance in AD links numerous treatment rationales. Pharmacol Rev, 2012. 64(4): p. 1004-26.
6. Dhawan, G. and C.K. Combs, Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of AD. J Neuroinflammation, 2012. 9: p. 117.
7. Drent, M., E.E. Lower, and J. De Vries, Sarcoidosis-associated fatigue. Eur Respir J, 2012. 40(1): p. 255-63.
8. Ferraccioli, G., et al., Rheumatoid Arthritis and AD: Possible Cellular and Molecular Links. Gerontology and Geriatric, 2012. 1(1).
9. Gabbita, S.P., et al., Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of AD. J Neuroinflammation, 2012. 9: p. 99.
10. Gruber, H.E., et al., Genome-wide analysis of pain-, nerve- and neurotrophin -related gene expression in the degenerating human annulus. Mol Pain, 2012. 8(1): p. 63.
11. Hojlund, J., et al., Effect of head rotation on cerebral blood velocity in the prone position. Anesthesiol Res Pract, 2012. 2012: p. 647258.
12. Ingles-Esteve, J., et al., Inhibition of specific NF-kappaB activity contributes to the tumor suppressor function of 14-3-3sigma in breast cancer. PLoS One, 2012. 7(5): p. e38347.
13. Jiang, T., J.T. Yu, and L. Tan, Novel disease-modifying therapies for AD. JAD, 2012. 31(3): p. 475-92.
14. Krishnadas, R. and J. Cavanagh, Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry, 2012. 83(5): p. 495-502.
15. Landoni, V.I., et al., Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity. PLoS Pathog, 2012. 8(3): p. e1002632.
16. Lauterbach, E.C., Psychotropic drug effects on gene transcriptomics relevant to AD. AD Assoc Disord, 2012. 26(1): p. 1-7.
17. Lima, A. and F. Antunes, Intervention of Physical Medicine and Rehabilitation in Failed Back Surgery Syndrome. Journal of Regional Anaesthesia and Pain Management, 2012. 68: p. 29-30.
18. Maccioni, R.B., et al., In Search of Therapeutic Solutions for AD, in When Things Go Wrong–Diseases and Disorders of the Human Brain, T. Mantamadiotis, Editor. 2012, InTech. p. 125-.
19. Matias-Guiu, J.A. and R. Garcia-Ramos, Primary progressive aphasia: from syndrome to disease. Neurologia, 2012.
20. Montgomery, S.L. and W.J. Bowers, Tumor Necrosis Factor-alpha and the Roles it Plays in Homeostatic and Degenerative Processes Within the Central Nervous System. Journal of Neuroimmune Pharmacology, 2012. 7(1): p. 42-59.
21. Ooi, L., et al., New drugs under development for AD, in Advances in AD Management, S. Gauthier and P. Rosa-Neto, Editors. 2012. p. 58-67.
22. Ramesh, V., et al., Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-alpha pathway. J Neuroinflammation, 2012. 9.
23. Santello, M. and A. Volterra, TNF-alpha in synaptic function: switching gears. Trends Neurosci, 2012. 35(10): p. 638-47.
24. Singh, P.L., et al., Current therapeutic strategies for inflammation following traumatic spinal cord injury. Neural Regeneration Research, 2012. 7(23): p. 1812-1821.
25. Steele, M.L. and S.R. Robinson, Reactive astrocytes give neurons less support: implications for AD. Neurobiol Aging, 2012. 33(2): p. 423 e1-13.
26. Stringer, M.D., et al., The vertebral venous plexuses: the internal veins are muscular and external veins have valves. Clin Anat, 2012. 25(5): p. 609-18.
27. Tweedie, D., et al., Tumor necrosis factor-alpha synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alz. pathology and behavioral deficits in animal models of neuroinflammation and AD. J Neuroinflammation, 2012. 9: p. 106.
28. Wilcock, D.M., Neuroinflammation in the aging down syndrome brain; lessons from AD. Curr Gerontol Geriatr Res, 2012. 2012: p. 170276.
29. Woodward, M.C., Drug treatments in development for AD. Journal of Pharmacy Practice and Research, 2012. 42(1): p. 58-65.
30. Yoshiyama, Y., V.M. Lee, and J.Q. Trojanowski, Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry, 2012.
- Therapeutic evaluation … in a model of traumatic brain injury.Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, Chang CP. J Neurochem. 2010 Nov;115(4):921-9.
- Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. Frankola KA, Greig NH, Luo W, Tweedie D. CNS Neurol Disord Drug Targets. 2011 Feb 2.
- Anti-TNF therapy in the injured spinal cord. Esposito E, Cuzzocrea S. Trends Pharmacol Sci. 2011 Feb;32(2):107-15. Epub 2010 Dec 23.
- …. antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS. Anesth Analg. 2011 Feb;112(2):454-9.
- Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J. Brain Res. 2011 Jan 12;1368:239-47.
- Attenuation of Inflammatory Events in Human Intervertebral Disc Cells with a Tumor Necrosis Factor Antagonist.Sinclair SM, Shamji MF, Chen J, Jing L, Richardson WJ, Brown CR, Fitch RD, Setton LA. Spine (Phila Pa 1976). 2011 Jan 6.
- Intrathecal inflammation precedes development of AD. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5.
- Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Park KM, Bowers WJ. Cell Signal. 2010 Jul;22(7):977-83.
- The roles of TNF in brain dysfunction and disease. Clark IA, Alleva LM, Vissel B. Pharmacol Ther. 2010 Dec;128(3):519-48.
- An association study of 21 potential AD risk genes in a Finnish population. Sarajärvi T, Helisalmi S, Antikainen L, Mäkinen P, Koivisto AM, Herukka SK, Haapasalo A, Soininen H, Hiltunen M. JAD. 2010;21(3):763-7.
- The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide.Medeiros R, Figueiredo CP, Pandolfo P, Duarte FS, Prediger RD, Passos GF, Calixto JB. Behav Brain Res. 2010 May 1;209(1):165-73.
- Soluble TNF receptors are associated with A-beta metabolism and conversion to dementia in subjects with mild cognitive impairment. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Neurobiol Aging. 2010 Nov;31(11):1877-84.
- Inflammation and anti-inflammatory strategies for AD–a mini-review. McNaull BB, Todd S, McGuinness B, Passmore AP. Gerontology. 2010;56(1):3-14.
- Systemic inflammation and disease progression in AD. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. Neurology. 2009 Sep 8;73(10):768-74.
- Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against ‘accepted wisdom’.Wolinsky H. EMBO Rep. 2008 May;9(5):416-8.
*Indicates that the Scientific Reference listed has cited one of more TransBarrier® Scientific Articles